Photodynamic Therapy of Malignant Gliomas

Prog Neurol Surg. 2018:32:1-13. doi: 10.1159/000469675. Epub 2018 Jul 10.

Abstract

Recently, the clinical applications of photodynamic therapy (PDT) in the management of malignant brain tumors have attracted significant attention. Meta-analysis of the observational studies on this treatment in high-grade gliomas (Eljamel, 2010) included more than 1,000 patients and reported median survival in cases of newly diagnosed and recurrent glioblastoma multiforme (GBM) of 16.1 and 10.3 months, respectively. In some series, increase in the long-term survival rates was also observed. Few controlled trials demonstrated statistically significant impact of PDT on prolongation of survival in patients with GBM in comparison to conventional management. The main treatment-related adverse event is short-lasting excessive photosensitivity of the skin and retina after photosensitizer administration, but its negative consequences can be easily avoided with appropriate protective measures. Overall, PDT may be considered to be a safe and effective adjuvant therapeutic option for patients with newly diagnosed and recurrent malignant gliomas. Aggressive tumor resection seems to be an important prerequisite to maximize treatment efficacy.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / therapy*
  • Glioma / drug therapy
  • Glioma / therapy*
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / therapy*
  • Outcome Assessment, Health Care*
  • Photochemotherapy / adverse effects
  • Photochemotherapy / methods*
  • Photosensitivity Disorders / etiology*
  • Photosensitizing Agents / adverse effects
  • Photosensitizing Agents / pharmacology*

Substances

  • Photosensitizing Agents